Nutrient-based therapies for bipolar disorder: A systematic review

Psychotherapy and Psychosomatics

Volumn 82, Issue 1, 2012, Pages 10-19

  Sylvia, Louisa G ^a,b   Peters, Amy T ^a   Deckersbach, Thilo ^a,b   Nierenberg, Andrew A ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Alternative treatments; Bipolar disorder; Nutrient based therapy

Indexed keywords

ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CHOLINE; CHROMIUM; CLONAZEPAM; CYANOCOBALAMIN; DOCOSAHEXAENOIC ACID; FISH OIL; FOLIC ACID; FOLIC ACID DERIVATIVE; FOLIC ACID METHYL ESTER; HALOPERIDOL; ICOSAPENTAENOIC ACID; ICOSAPENTAENOIC ACID ETHYL ESTER; INOSITOL; LAMOTRIGINE; LINSEED OIL; LITHIUM; MAGNESIUM; MAGNESIUM OXIDE; MAGNESIUM SULFATE; MOOD STABILIZER; OMEGA 3 FATTY ACID; PLACEBO; PYRIDOXINE; RISPERIDONE; TRYPTOPHAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VERAPAMIL;

ANTIDEPRESSANT ACTIVITY; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; BIPOLAR MANIA; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL GLOBAL IMPRESSION SCALE; DEPRESSION; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG MECHANISM; EOSINOPHILIA MYALGIA SYNDROME; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; MEDLINE; PRIORITY JOURNAL; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RAPID CYCLING BIPOLAR DISORDER; REVIEW; SAMPLE SIZE; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BIPOLAR DISORDER; CHOLINE; CHROMIUM; DIETARY SUPPLEMENTS; FATTY ACIDS, OMEGA-3; FOLIC ACID; HUMANS; INOSITOL; LIPOTROPIC AGENTS; MAGNESIUM; TRACE ELEMENTS; TRYPTOPHAN; VITAMIN B COMPLEX;

EID: 84868606212     PISSN: 00333190     EISSN: 14230348     Source Type: Journal    
DOI: 10.1159/000341309     Document Type: Review

References (124)

1. Keitner GI, Solomon DA, Ryan CE, Miller IW, Mallinger A, Kupfer DJ, Frank E: Prodromal and residual symptoms in bipolar I disorder. Compr Psychiatry 1996; 37: 362-367.
2. Sajatovic M, Valenstein M, Blow F, Ganoczy D, Ignacio R: Treatment adherence with lithium and anticonvulsant medications among patients with bipolar disorder. Psychiatr Serv 2007; 58: 855-863.
3. Lingam R, Scott J: Treatment non-adherence in affective disorders. Acta Psychiatr Scand 2002; 105: 164-172.
4. Correll CU: Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials. J Am Acad Child Adolesc Psychiatry 2007; 46: 687-700.
5. Culver JL, Arnow BA, Ketter TA: Bipolar disorder: Improving diagnosis and optimizing integrated care. J Clin Psychol 2007; 63: 73-92.
6. Simopoulos AP: Essential fatty acids in health and chronic disease. Am J Clin Nutr 1999; 70: 560S-569S.
7. Hu FB, Willett WC: Optimal diets for prevention of coronary heart disease. JAMA 2002; 288: 2569-2578.
8. Cleland LG, James MJ, Proudman SM: The role of fish oils in the treatment of rheumatoid arthritis. Drugs 2003; 63: 845-853.
9. Uauy R, Peirano P, Hoffman D, Mena P, Birch D, Birch E: Role of essential fatty acids in the function of the developing nervous system. Lipids 1996; 31(suppl):S167-S176.
10. Wainwright PE: Dietary essential fatty acids and brain function: a developmental perspective on mechanisms. Proc Nutr Soc 2002; 61: 61-69.
11. Salem N Jr, Litman B, Kim HY, Gawrisch K: Mechanisms of action of docosahexaenoic acid in the nervous system. Lipids 2001; 36: 945-959.
12. Horrobin DF, Bennett CN: Depression and bipolar disorder: relationships to impaired fatty acid and phospholipid metabolism and to diabetes, cardiovascular disease, immunological abnormalities, cancer, ageing and osteoporosis. Possible candidate genes. Prostaglandins Leukot Essent Fatty Acids 1999; 60: 217-234.
13. Ayton AK, Azaz A, Horrobin DF: A pilot open case series of ethyl-EPA supplementation in the treatment of anorexia nervosa. Prostaglandins Leukot Essent Fatty Acids 2004; 71: 205-209.
14. Buydens-Branchey L, Branchey M, Hibbeln JR: Associations between increases in plasma n-3 polyunsaturated fatty acids following supplementation and decreases in anger and anxiety in substance abusers. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 568-575.
15. Arvindakshan M, Sitasawad S, Debsikdar V, Ghate M, Evans D, Horrobin DF, Bennett C, Ranjekar PK, Mahadik SP: Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients. Biol Psychiatry 2003; 53: 56-64.
16. Holman RT, Adams CE, Nelson RA, Grater SJ, Jaskiewicz JA, Johnson SB, Erdman JW Jr: Patients with anorexia nervosa demonstrate deficiencies of selected essential fatty acids, compensatory changes in nonessential fatty acids and decreased fluidity of plasma lipids. J Nutr 1995; 125: 901-907.
17. Kim SY, Breslow RA, Ahn J, Salem N Jr: Alcohol consumption and fatty acid intakes in the 2001-2002 national health and nutrition examination survey. Alcohol Clin Exp Res 2007; 31: 1407-1414.
18. Horrobin DF: Essential fatty acids, prostaglandins, and alcoholism: an overview. Alcohol Clin Exp Res 1987; 11: 2-9.
19. Green P, Hermesh H, Monselise A, Marom S, Presburger G, Weizman A: Red cell membrane omega-3 fatty acids are decreased in nondepressed patients with social anxiety disorder. Eur Neuropsychopharmacol 2006; 16: 107-113.
20. Peet M, Horrobin DF: A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry 2002; 59: 913-919.
21. Peet M, Horrobin DF: A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J Psychiatr Res 2002; 36: 7-18.
22. Buydens-Branchey L, Branchey M: n-3 polyunsaturated fatty acids decrease anxiety feelings in a population of substance abusers. J Clin Psychopharmacol 2006; 26: 661-665.
23. Elmslie JL, Mann JI, Silverstone JT, Williams SM, Romans SE: Determinants of overweight and obesity in patients with bipolar disorder. J Clin Psychiatry 2001; 62: 486-491.
24. Killbourne AM, Rofey DL, McCarthy JF, Post EP, Welsh D, Blow FC: Nutrition and exercise behavior among patients with bipolar disorder. Bipolar Disord 2007; 9: 443-452.
25. Lee YS: The role of leptin-melanocortin system and human weight regulation: lessons from experiments of nature. Ann Acad Med Singapore 2009; 38: 34-11.
26. Lakhan SE, Vieira KF: Nutritional therapies for mental disorders. Nutr J 2008; 7: 2.
27. Davison KM, Kaplan BJ: Vitamin and mineral intakes in adults with mood disorders: comparisons to nutrition standards and associations with sociodemographic and clinical variables. J Am Coll Nutr 2011; 30: 547-558.
28. Cohen BM, Lipinski JF, Altesman RI: Lecithin in the treatment of mania: double-blind, placebo-controlled trials. Am J Psychiatry 1982; 139: 1162-1164.
29. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D: The prisma statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339:b2700.
30. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 3. Washington, Psychiatric Press, 1980.
31. American Psychiatric Association: Diagnostic and Statistical Manual for Mental Disorders, ed 4 (DSM-IV). Washington, Psychiatric Press, 1994.
32. Fava GA: Unmasking special interest groups: the key to addressing conflicts of interest in medicine. Psychother Psychosom 2010; 79: 203-207.
33. Stansby ME: Nutritional properties of fish oils. World Rev Nutr Diet 1969; 11: 46-105.
34. Sperling RI, Benincaso AI, Knoell CT, Larkin JK, Austen KF, Robinson DR: Dietary omega-3 polyunsaturated fatty acids inhibit phosphoinositide formation and chemotaxis in neutrophils. J Clin Invest 1993; 91: 651-660.
35. Tappia PS, Ladha S, Clark DC, Grimble RF: The influence of membrane fluidity, TNF receptor binding, cAMP production and GTPase activity on macrophage cytokine production in rats fed a variety of fat diets. Mol Cell Biochem 1997; 166: 135-143.
36. Mischoulon D, Rosenbaum JF: Natural Medications for Psychiatric Disorders: Considering the Alternatives, ed 2. Philadelphia, Lippincott Williams & Wilkins, 2008.
37. Balanza-Martinez V, Fries GR, Colpo GD, Silveira PP, Portella AK, Tabares-Seisdedos R, Kapczinski F: Therapeutic use of omega-3 fatty acids in bipolar disorder. Expert Rev Neurother 2011; 11: 1029-1047.
38. Stoll AL, Severus WE, Freeman MP, Rueter S, Zboyan HA, Diamond E, Cress KK, Marangell LB: Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry 1999; 56: 407-412.
39. Frangou S, Lewis M, McCrone P: Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebocontrolled study. Br J Psychiatry 2006; 188: 46-50.
40. Keck PE Jr, Mintz J, McElroy SL, Freeman MP, Suppes T, Frye MA, Altshuler LL, Kupka R, Nolen WA, Leverich GS, Denicoff KD, Grunze H, Duan N, Post RM: Double-blind, randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder. Biol Psychiatry 2006; 60: 1020-1022.
41. Chiu CC, Huang SY, Chen CC, Su KP: Omega-3. fatty acids are more beneficial in the depressive phase than in the manic phase in patients with bipolar I disorder. J Clin Psychiatry 2005; 66: 1613-1614.
42. Osher Y, Bersudsky Y, Belmaker RH: Omega-3. eicosapentaenoic acid in bipolar depression: report of a small open-label study. J Clin Psychiatry 2005; 66: 726-729.
43. Sagduyu K, Dokucu ME, Eddy BA, Craigen G, Baldassano CF, Yildiz A: Omega-3 fatty acids decreased irritability of patients with bipolar disorder in an add-on, open label study. Nutr J 2005; 4: 6.
44. Clayton EH, Hanstock TL, Hirneth SJ, Kable CJ, Garg ML, Hazell PL: Reduced mania and depression in juvenile bipolar disorder associated with long-chain omega-3 polyunsaturated fatty acid supplementation. Eur J Clin Nutr 2009; 63: 1037-1040.
45. Wozniak J, Biederman J, Mick E, Waxmonsky J, Hantsoo L, Best C, Cluette-Brown JE, Laposata M: Omega-3 fatty acid monotherapy for pediatric bipolar disorder: a prospective open-label trial. Eur Neuropsychopharmacol 2007; 17: 440-447.
46. Marangell LB, Suppes T, Ketter TA, Dennehy EB, Zboyan H, Kertz B, Nierenberg A, Calabrese J, Wisniewski SR, Sachs G: Omega-3 fatty acids in bipolar disorder: clinical and research considerations. Prostaglandins Leukot Essent Fatty Acids 2006; 75: 315-321.
47. Gracious BL, Chirieac MC, Costescu S, Finucane TL, Youngstrom EA, Hibbeln JR: Randomized, placebo-controlled trial of flax oil in pediatric bipolar disorder. Bipolar Disord 2010; 12: 142-154.
48. Levine J, Barak Y, Gonzalves M, Szor H, Elizur A, Kofman O, Belmaker RH: Doubleblind, controlled trial of inositol treatment of depression. Am J Psychiatry 1995; 152: 792-794.
49. Nierenberg AA, Ostacher MJ, Calabrese JR, Ketter TA, Marangell LB, Miklowitz DJ, Miyahara S, Bauer MS, Thase ME, Wisniewski SR, Sachs GS: Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry 2006; 163: 210-216.
50. Chengappa KN, Levine J, Gershon S, Mallinger AG, Hardan A, Vagnucci A, Pollock B, Luther J, Buttenfield J, Verfaille S, Kupfer DJ: Inositol as an add-on treatment for bipolar depression. Bipolar Disord 2000; 2: 47-55.
51. Eden Evins A, Demopulos C, Yovel I, Culhane M, Ogutha J, Grandin LD, Nierenberg AA, Sachs GS: Inositol augmentation of lithium or valproate for bipolar depression. Bipolar Disord 2006; 8: 168-174.
52. Lyoo IK, Demopulos CM, Hirashima F, Ahn KH, Renshaw PF: Oral choline decreases brain purine levels in lithium-treated subjects with rapid-cycling bipolar disorder: a double-blind trial using proton and lithium magnetic resonance spectroscopy. Bipolar Disord 2003; 5: 300-306.
53. Citicoline. Monograph. Altern Med Rev 2008; 13: 50-57.
54. Clay HB, Sillivan S, Konradi C: Mitochondrial dysfunction and pathology in bipolar disorder and schizophrenia. Int J Dev Neurosci 2011; 29: 311-324.
55. Andreazza AC, Shao L, Wang JF, Young LT: Mitochondrial complex I activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder. Arch Gen Psychiatry 2010; 67: 360-368.
56. Chen G, Henter ID, Manji HK: Translational research in bipolar disorder: emerging insights from genetically based models. Mol Psychiatry 2010; 15: 883-895.
57. Yuksel C, Ongur D: Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders. Biol Psychiatry 2010; 68: 785-794.
58. Stork C, Renshaw PF: Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research. Mol Psychiatry 2005; 10: 900-919.
59. Frazier JA, Ahn MS, De Jong S, Bent EK, Breeze JL, Giuliano AJ: Magnetic resonance imaging studies in early-onset bipolar disorder: a critical review. Harv Rev Psychiatry 2005; 13: 125-140.
60. Patel NC, Cecil KM, Strakowski SM, Adler CM, Del Bello MP: Neurochemical alterations in adolescent bipolar depression: a proton magnetic resonance spectroscopy pilot study of the prefrontal cortex. J Child Adolesc Psychopharmacol 2008; 18: 623-627.
61. Brown ES, Gorman AR, Hynan LS: A randomized, placebo-controlled trial of citicoline add-on therapy in outpatients with bipolar disorder and cocaine dependence. J Clin Psychopharmacol 2007; 27: 498-502.
62. Stoll AL, Sachs GS, Cohen BM, Lafer B, Christensen JD, Renshaw PF: Choline in the treatment of rapid-cycling bipolar disorder: clinical and neurochemical findings in lithium-treated patients. Biol Psychiatry 1996; 40: 382-388.
63. Schimatschek HF, Rempis R: Prevalence of hypomagnesemia in an unselected German population of 16,000 individuals. Magnes Res 2001; 14: 283-290.
64. Bowden CL: Anticonvulsants in bipolar disorders: current research and practice and future directions. Bipolar Disord 2009; 11(suppl 2):20-33.
65. Yildiz A, Guleryuz S, Ankerst DP, Ongur D, Renshaw PF: Protein kinase C inhibition in the treatment of mania: a double-blind, placebo-controlled trial of tamoxifen. Arch Gen Psychiatry 2008; 65: 255-263.
66. Zarate CA, Manji HK: Protein kinase C inhibitors: rationale for use and potential in the treatment of bipolar disorder. CNS Drugs 2009; 23: 569-582.
67. Siwek M, Wrobel A, Dudek D, Nowak G, Zieba A: The role of copper and magnesium in the pathogenesis and treatment of affective disorders. Psychiatr Pol 2005; 39: 911-920.
68. Murck H: Magnesium and affective disorders. Nutr Neurosci 2002; 5: 375-389.
69. Giannini AJ, Houser WL Jr, Loiselle RH, Giannini MC, Price WA: Antimanic effects of verapamil. Am J Psychiatry 1984; 141: 1602-1603.
70. Giannini AJ, Nakoneczie AM, Melemis SM, Ventresco J, Condon M: Magnesium oxide augmentation of verapamil maintenance therapy in mania. Psychiatry Res 2000; 93: 83-87.
71. Heiden A, Frey R, Presslich O, Blasbichler T, Smetana R, Kasper S: Treatment of severe mania with intravenous magnesium sulphate as a supplementary therapy. Psychiatry Res 1999; 89: 239-246.
72. Chouinard G, Beauclair L, Geiser R, Etienne P: A pilot study of magnesium aspartate hydrochloride (magnesiocard) as a mood stabilizer for rapid cycling bipolar affective disorder patients. Prog Neuropsychopharmacol Biol Psychiatry 1990; 14: 171-180.
73. Horacek J, Kuzmiakova M, Hoschl C, Andel M, Bahbonh R: The relationship between central serotonergic activity and insulin sensitivity in healthy volunteers. Psychoneuroendocrinology 1999; 24: 785-797.
74. Liu PS, Lin MK: Biphasic effects of chromium compounds on catecholamine secretion from bovine adrenal medullary cells. Toxicology 1997; 117: 45-53.
75. McCarty MF: Longevity effect of chromium picolinate-'rejuvenation' of hypothalamic function? Med Hypotheses 1994; 43: 253-265.
76. Wright JH, Jacisin JJ, Radin NS, Bell RA: Glucose metabolism in unipolar depression. Br J Psychiatry 1978; 132: 386-393.
77. McLeod MN, Gaynes BN, Golden RN: Chromium potentiation of antidepressant pharmacotherapy for dysthymic disorder in 5 patients. J Clin Psychiatry 1999; 60: 237-240.
78. McLeod MN, Golden RN: Chromium treatment of depression. Int J Neuropsychopharmacol 2000; 3: 311-314.
79. Davidson JR, Abraham K, Connor KM, McLeod MN: Effectiveness of chromium in atypical depression: a placebo-controlled trial. Biol Psychiatry 2003; 53: 261-264.
80. Amann BL, Mergl R, Vieta E, Born C, Hermisson I, Seemueller F, Dittmann S, Grunze H: A 2-year, open-label pilot study of adjunctive chromium in patients with treatmentresistant rapid-cycling bipolar disorder. J Clin Psychopharmacol 2007; 27: 104-106.
81. Mischoulon D, Raab MF: The role of folate in depression and dementia. J Clin Psychiatry 2007; 68(suppl 10):28-33.
82. Calvaresi E, Bryan J: B vitamins, cognition, and aging: a review. J Gerontol B Psychol Sci Soc Sci 2001; 56:P327-P339.
83. Godfrey PS, Toone BK, Carney MW, Flynn TG, Bottiglieri T, Laundy M, Chanarin I, Reynolds EH: Enhancement of recovery from psychiatric illness by methylfolate. Lancet 1990; 336: 392-395.
84. McKeon P, Shelley R, O'Regan S, O'Broin J: Serum and red cell folate and affective morbidity in lithium prophylaxis. Acta Psychiatr Scand 1991; 83: 199-201.
85. Bourre JM: Effects of nutrients (in food) on the structure and function of the nervous system: update on dietary requirements for brain. 2. Macronutrients. J Nutr Health Aging 2006; 10: 386-399.
86. Hannon-Fletcher MP, Armstrong NC, Scott JM, Pentieva K, Bradbury I, Ward M, Strain JJ, Dunn AA, Molloy AM, Kerr MA, McNulty H: Determining bioavailability of food folates in a controlled intervention study. Am J Clin Nutr 2004; 80: 911-918.
87. Selhub J, Bagley LC, Miller J, Rosenberg IH: B vitamins, homocysteine, and neurocognitive function in the elderly. Am J Clin Nutr 2000; 71: 614S-620S.
88. Nehra R, Chakrabarti S, Pradhan BK, Khehra N: Comparison of cognitive functions between first-and multi-episode bipolar affective disorders. J Affect Disord 2006; 93: 185-192.
89. Reynolds EH: Folic acid, ageing, depression, and dementia. BMJ 2002; 324: 1512-1515.
90. Bryan J, Calvaresi E, Hughes D: Short-term folate, vitamin B 12 or vitamin B 6 supplementation slightly affects memory performance but not mood in women of various ages. J Nutr 2002; 132: 1345-1356.
91. Behzadi AH, Omrani Z, Chalian M, Asadi S, Ghadiri M: Folic acid efficacy as an alternative drug added to sodium valproate in the treatment of acute phase of mania in bipolar disorder: a double-blind randomized controlled trial. Acta Psychiatr Scand 2009; 120: 441-445.
92. Hasanah CI, Khan UA, Musalmah M, Razali SM: Reduced red-cell folate in mania. J Affect Disord 1997; 46: 95-99.
93. Carney MW, Chary TK, Laundy M, Bottiglieri T, Chanarin I, Reynolds EH, Toone B: Red cell folate concentrations in psychiatric patients. J Affect Disord 1990; 19: 207-213.
94. Lazarou C, Kapsou M: The role of folic acid in prevention and treatment of depression: an overview of existing evidence and implications for practice. Complement Ther Clin Pract 2010; 16: 161-166.
95. Coppen A, Bailey J: Enhancement of the antidepressant action of fluoxetine by folic acid: a randomised, placebo controlled trial. J Affect Disord 2000; 60: 121-130.
96. Bell C, Abrams J, Nutt D: Tryptophan depletion and its implications for psychiatry. Br J Psychiatry 2001; 178: 399-405.
97. Smith KA, Fairburn CG, Cowen PJ: Relapse of depression after rapid depletion of tryptophan. Lancet 1997; 349: 915-919.
98. Delgado PL, Charney DS, Price LH, Aghajanian GK, Landis H, Heninger GR: Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry 1990; 47: 411-418.
99. Bremner JD, Innis RB, Salomon RM, Staib LH, Ng CK, Miller HL, Bronen RA, Krystal JH, Duncan J, Rich D, Price LH, Malison R, Dey H, Soufer R, Charney DS: Positron emission tomography measurement of cerebral metabolic correlates of tryptophan depletion-induced depressive relapse. Arch Gen Psychiatry 1997; 54: 364-374.
100. Aberg-Wistedt A, Hasselmark L, Stain-Malmgren R, Aperia B, Kjellman BF, Mathe AA: Serotonergic 'vulnerability' in affective disorder: a study of the tryptophan depletion test and relationships between peripheral and central serotonin indexes in citalopram-responders. Acta Psychiatr Scand 1998; 97: 374-380.
101. Leyton M, Young SN, Pihl RO, Etezadi S, Lauze C, Blier P, Baker GB, Benkelfat C: Effects on mood of acute phenylalanine/tyrosine depletion in healthy women. Neuropsychopharmacology 2000; 22: 52-63.
102. Chouinard G: The search for new off-label indications for antidepressant, antianxiety, antipsychotic and anticonvulsant drugs. J Psychiatry Neurosci 2006; 31: 168-176.
103. Applebaum J, Bersudsky Y, Klein E: Rapid tryptophan depletion as a treatment for acute mania: a double-blind, pilot-controlled study. Bipolar Disord 2007; 9: 884-887.
104. Chouinard G, Young SN, Annable L: A controlled clinical trial of L-tryptophan in acute mania. Biol Psychiatry 1985; 20: 546-557.
105. Centers for Disease Control: Eosinophiliamyalgia syndrome associated with ingestion of L-tryptophan-United States, through August 24, 1990. JAMA 1990; 264: 1655.
106. Kamb ML, Murphy JJ, Jones JL, Caston JC, Nederlof K, Horney LF, Swygert LA, Falk H, Kilbourne EM: Eosinophilia-myalgia syndrome in L-tryptophan-exposed patients. JAMA 1992; 267: 77-82.
107. Nordentoft M: Prevention of suicide and attempted suicide in Denmark. Epidemiological studies of suicide and intervention studies in selected risk groups. Dan Med Bull 2007; 54: 306-369.
108. Jacka FN, Pasco JA, Mykletun A, Williams LJ, Nicholson GC, Kotowicz MA, Berk M: Diet quality in bipolar disorder in a population-based sample of women. J Affect Disord 2011; 129: 332-337.
109. Liu S, Manson JE, Buring JE, Stampfer MJ, Willett WC, Ridker PM: Relation between a diet with a high glycemic load and plasma concentrations of high-sensitivity C-reactive protein in middle-aged women. Am J Clin Nutr 2002; 75: 492-498.
110. Molteni R, Barnard RJ, Ying Z, Roberts CK, Gomez-Pinilla F: A high-fat, refined sugar diet reduces hippocampal brain-derived neurotrophic factor, neuronal plasticity, and learning. Neuroscience 2002; 112: 803-814.
111. Kapczinski F, Frey BN, Kauer-Sant'Anna M, Grassi-Oliveira R: Brain-derived neurotrophic factor and neuroplasticity in bipolar disorder. Expert Rev Neurother 2008; 8: 1101-1113.
112. Sanchez-Villegas A, Delgado-Rodriguez M, Alonso A, Schlatter J, Lahortiga F, Serra Majem L, Martinez-Gonzalez MA: Association of the Mediterranean dietary pattern with the incidence of depression: The Seguimiento Universidad de Navarra/University of Navarra Follow-Up (SUN) cohort. Arch Gen Psychiatry 2009; 66: 1090-1098.
113. Jacka FN, Pasco JA, Mykletun A, Williams LJ, Hodge AM, O'Reilly SL, Nicholson GC, Kotowicz MA, Berk M: Association of western and traditional diets with depression and anxiety in women. Am J Psychiatry 2010; 167: 305-311.
114. Akbaraly TN, Brunner EJ, Ferrie JE, Marmot MG, Kivimaki M, Singh-Manoux A: Dietary pattern and depressive symptoms in middle age. Br J Psychiatry 2009; 195: 408-413.
115. Jacka FN, Pasco JA, Williams LJ, Mann N, Hodge A, Brazionis L, Berk M: Red meat consumption and mood and anxiety disorders. Psychother Psychosom 2012; 81: 196-198.
116. Blair SN, Kohl HW 3rd, Barlow CE, Paffenbarger RS Jr, Gibbons LW, Macera CA: Changes in physical fitness and all-cause mortality. A prospective study of healthy and unhealthy men. JAMA 1995; 273: 1093-1098.
117. Church TS, Earnest CP, Skinner JS, Blair SN: Effects of different doses of physical activity on cardiorespiratory fitness among sedentary, overweight or obese postmenopausal women with elevated blood pressure: a randomized controlled trial. JAMA 2007; 297: 2081-2091.
118. Cornelissen VA, Fagard RH: Effects of endurance training on blood pressure, blood pressure-regulating mechanisms, and cardiovascular risk factors. Hypertension 2005; 46: 667-675.
119. Sylvia LG, Ametrano RM, Nierenberg AA: Exercise treatment for bipolar disorder: potential mechanisms of action mediated through increased neurogenesis and decreased allostatic load. Psychother Psychosom 2010; 79: 87-96.
120. Gomes BC, Abreu LN, Brietzke E, Caetano SC, Kleinman A, Nery FG, Lafer B: A randomized controlled trial of cognitive behavioral group therapy for bipolar disorder. Psychother Psychosom 2011; 80: 144-150.
121. Miklowitz DJ, Otto MW: Psychosocial interventions for bipolar disorder: A review of literature and introduction of the systematic treatment enhancement program. Psychopharmacol Bull 2007; 40: 116-131.
122. Sylvia LG, Nierenberg AA, Stange JP, Peckham AD, Deckersbach T: Development of an integrated psychosocial treatment to address the medical burden associated with bipolar disorder. J Psychiatr Pract 2011; 17: 224-232.
123. Baldessarini RJ, Vazquez G, Tondo L: Treatment of cyclothymic disorder: commentary. Psychother Psychosom 2011; 80: 131-135.
124. Fava GA, Rafanelli C, Tomba E, Guidi J, Grandi S: The sequential combination of cognitive behavioral treatment and wellbeing therapy in cyclothymic disorder. Psychother Psychosom 2011; 80: 136-143.